Back to results
US 2004/0002585 A1Published application
Mucin fusion polypeptide vaccines, compositions and methods of use thereof
AssigneeRecopharma AB
InventorJan Holgersson
Life of this patent
Estimating the term…
Abstract
The present invention provides compositions and methods for augmenting vaccine immunogenicity using mucin-immunoglobulin fusion proteins.
Claims28
A purified vaccine comprising:
- (a) an adjuvant polypeptide comprising a first polypeptide operably linked to a second polypeptide, wherein the first polypeptide is a mucin polypeptide and is glycosylated by a α1,3 galactosyltransferase and the second polypeptide comprises at least a region of an immunoglobulin polypeptide and
- (b) an antigen.
A method of increasing antibody secretion in a cell, comprising contacting said cell with a purified vaccine, said vaccine comprising:
- (a) an adjuvant polypeptide comprising a first polypeptide operably linked to a second polypeptide, wherein the first polypeptide is a mucin polypeptide and is glycosylated by a α1,3 galactosyltransferase and the second polypeptide comprises at least a region of an immunoglobulin polypeptide and
- (b) an antigen,
- such that the antibody secretion in said cell is increased.
A method of increasing immune cell activation, comprising contacting said immune cell with a purified vaccine, said vaccine comprising:
- (a) an adjuvant polypeptide comprising a first polypeptide operably linked to a second polypeptide, wherein the first polypeptide is a mucin polypeptide and is glycosylated by a α1,3 galactosyltransferase and the second polypeptide comprises at least a region of an immunoglobulin polypeptide and
- (b) an antigen,
- such that the activation of said cell is increased.
Dependencies are inferred from the claim text.